HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp

State Street Corp grew its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 0.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 349,524 shares of the company’s stock after buying an additional 3,078 shares during the period. State Street Corp owned about 0.20% of HUTCHMED worth $6,826,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Point72 Hong Kong Ltd acquired a new position in shares of HUTCHMED in the 3rd quarter valued at about $421,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock worth $952,000 after acquiring an additional 24,245 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new position in HUTCHMED in the third quarter valued at approximately $328,000. M&G PLC grew its holdings in shares of HUTCHMED by 98.1% during the third quarter. M&G PLC now owns 267,231 shares of the company’s stock valued at $5,345,000 after purchasing an additional 132,333 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of HUTCHMED by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock worth $117,000 after purchasing an additional 2,321 shares during the period. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Stock Performance

NASDAQ HCM opened at $14.27 on Friday. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The business’s fifty day moving average is $17.45 and its two-hundred day moving average is $18.01. HUTCHMED has a 1 year low of $11.93 and a 1 year high of $21.92.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.